May 25, 2000 - Issue: Vol. 146, No. 67 — Daily Edition106th Congress (1999 - 2000) - 2nd Session
OUTRAGEOUSLY HIGH DRUG PRICES IN THE UNITED STATES
(House of Representatives - May 25, 2000)
Text available as:
Formatting necessary for an accurate reading of this text may be shown by tags (e.g., <DELETED> or <BOLD>) or may be missing from this TXT display. For complete and accurate display of this text, see the PDF.
[Pages H3858-H3859] From the Congressional Record Online through the Government Publishing Office [www.gpo.gov] OUTRAGEOUSLY HIGH DRUG PRICES IN THE UNITED STATES The SPEAKER pro tempore. Under a previous order of the House, the gentleman from Minnesota (Mr. Gutknecht) is recognized for 5 minutes. Mr. GUTKNECHT. Mr. Speaker, today I rise to speak again about an issue, that, as Members go back to their districts and have town hall meetings, I am certain they are going to hear about. The issue I want to talk about this afternoon is the issue of outrageously high drug prices that we pay in the United States, especially when we compare what Americans pay to what consumers around the rest of the world pay. What I have here is a chart, and our source is the Life Extension Network. They did research recently and compared the average prices for commonly prescribed drugs in the United States to what the average prices are in Europe. And it really is sobering. For example, Premarin is a commonly prescribed drug, the same drug made in the same plant under the same FDA approval, incidentally. In the United States, the average price is $14.98. For that exact same drug in the same quantity in Europe they pay $4.25. Coumadin is a drug that my dad takes; it is a blood thinner. In the United States, the average price is $30.25, but in Europe they pay only $2.85. And the list goes on. Prilosec, another commonly prescribed drug in the United States, the average price here in the United States is over $100; in Europe they are paying $39.25. Claritin, very commonly prescribed drug, particularly this time of year for hayfever and allergies, the United States is $44 an average; over in Europe, they are paying $8.75. The list goes on and on and on. And I think the story is altogether too familiar. Mr. Speaker, I would ask my colleagues to ask themselves this simple question: Can any of us think of another product of any kind where the world's best customers pay the world's highest prices? This is particularly troubling because just yesterday we had a vote on expanding trade opportunities in opening markets between the United States and China. We have had for several years now the North American Free Trade Agreement. Goods and services are supposed to flow across our borders with Canada and Mexico freely. Recent studies suggest, and this is a study done by the Canadian government, says that Americans are paying 56 percent more for the same prescription drugs made in the same facilities under the same FDA approval than our Canadian friends are paying for those same drugs. In other words, we are paying 56 percent more than Canadians, and the story gets worse. Prices in Mexico are [[Page H3859]] even lower. Consumers have been learning about this, and particularly seniors. In Minnesota and all across the country, particularly where we are closer to the borders, seniors especially are getting on buses, and they are going to Canada to buy their prescription drugs. We have this wide disparity between what we pay and what the rest of the world pays. The question has to be asked, the people who are supposed to protect us are our own FDA, the Food and Drug Administration. So one might ask, what are they doing to help consumers get lower prices? Well, here is the answer. This is an edited version, but I want to point out a couple of sentences. We do not have the whole letter here, but it is available. Anyone who would like a copy can call my office. What the FDA is doing to help consumers is they are threatening them. If someone tries to order drugs through a mail order house from the United States, what they get with the order that has been opened is a threatening letter. Let me just read it. It says, ``Dear consumer: This letter is to advise you that the Minneapolis District of the United States Food and Drug Administration has examined a package addressed to you containing drugs which appear to be unapproved for use in the United States.'' Well, Mr. Speaker, that is not true. The vast majority of drugs that are coming via this method are legal drugs in the United States. They are approved by the FDA. They are made in exactly the same plants. Later it says, ``Because you are taking this medication under the care of a physician and we do not want to cause your medical treatment to be unduly affected, we are releasing this shipment. However,'' and this is the important line, ``future shipments of these or similar drugs may be refused admission.'' Now, if one were a 75-year-old grandmother and they get a threatening letter from the FDA, it is very disconcerting. Mr. Speaker, I think it is time for Congress to take a serious look at this problem. If we could just simply recover part of the costs, the differentials that we are paying for prescription drugs, we could go a long way to solving the problem of those people who fall through the cracks. Do not just take my word for it. We just received in our offices a little pamphlet from Blue Cross/Blue Shield. Let me just read from it. It says, ``Spending on prescription drugs rose 84 percent between 1993 and 1998.'' Mr. Speaker, it is time for Congress to say that the FDA should not stand between our consumers and lower drug prices. ____________________